Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$161.18M+2.30%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Martin D. Madaus
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 2,900
- Beta
- 1.39
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 4.18
Financials
Revenue
$161.18M+2.3%Net Income
$2.46M-76.7%EBITDA
$14.43M-15.1%Free Cash Flow
$-3.87M-119.3%EPS (diluted)
$0.05-66.7%Shares Outstanding (diluted)
45.29M-34.9%Operating Expenses
$76.02MCash & Debt
$325.80MReturn of Capital
$50.05MRevenue by Segment (annual)
$593.82MDividend per Share
$0.10Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $593.82M | $-55.76M | $-1.22 |
| 2024 | $573.45M | $-164.90M | $-3.09 |
| 2023 | $665.07M | $-14.26M | $-0.22 |
| 2022 | $555.50M | $-428.96M | $-0.15 |
| 2021 | $513.70M | $110.75M | $1.49 |
| 2020 | $388.54M | $64.85M | $0.88 |
| 2019 | $780.85M | $28.82M | $0.14 |
| 2018 | $631.56M | $116.58M | $1.65 |
| 2017 | $527.50M | $62.61M | $0.90 |
| 2016 | $560.32M | $-69.48M | $-1.02 |
| 2015 | $552.71M | $14.22M | $0.21 |
| 2014 | $482.85M | $4.46M | $0.47 |
| 2013 | $422.44M | $-2.21M | $-0.03 |
| 2012 | $519.45M | $136.79M | $2.10 |
Valuation
AZTAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-33.33%Social Signal Score
Mentions (2)
- Newsprnewswire.com·32d ago·Negative
Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems BURLINGTON, Mass., Sept. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has received repayment in full, prior to maturity, of the $35 million secured vendor loan extended in connection with the previously announced sale of B Medical Systems S.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Azenta: Needs To Overcome A Few Hurdles If The Rally Is To Continue AZTA went down for a long time, resulting in a multi-year low in May 2026, but the stock has rallied higher since then. While the stock has doubled in value, there is a chart that suggests to be wary of the rally because it could unwind itself in the near future. The current financial model from AZTA makes a case for being long, but that depends on whether AZTA can hit the targets laid out.
View source ↗
Earnings
Fri, Nov 20(in 6 weeks)
Consensus estimate $0.09 per share
Typical surprise +10.8% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.16 vs $0.11beat
- Wed, May 6$-0.04 vs $0.10miss
- Wed, Feb 4$0.09 vs $0.11miss
- Fri, Nov 21$0.21 vs $0.19beat
- Tue, Aug 5$0.19 vs $0.13beat
- Wed, May 7$0.05 vs $0.09miss
Estimates and results for AZTA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AZTA officers and directors.
- Bought
- $2.1m
- Sold
- $224k
14 trades
10 trades
- Starr Ephraimbought
- Cornog William Lbought
- Marotta Johnsold
- Pirogova Olgasold
- Zhou Gingersold
- Lin Lawrence Y.bought
- Marotta Johnbought
- Malus Alan Jbought
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Feb 13, 2026 (29d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Nov 18, 2025 (40d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Apr 11, 2025 (23d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 15, 2023 (30d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 21, 2023 (38d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 11, 2023 (28d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 10, 2022 (38d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 10, 2022 (26d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.